Seeking Alpha

Qniform

Qniform
Send Message
View as an RSS Feed
View Qniform's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead's Stock Price, Harvoni Pricing, And The Threat Of Merck- A Physician's Perspective [View article]
    I think I know what you mean franky, but I'll add the obvious here. Greed is not good. Every man for himself is not good. Saying that these things are "good" is perverse. The regulated system of competing interests that we have in the US has worked pretty well for a little while (in historic terms). That pragmatic result says little about the human flaws it attempts to control.

    The problem is the human heart. No economic or political system can motivate through greed or fear what is lacking in morality and ethics.
    Aug 6, 2015. 09:33 AM | 2 Likes Like |Link to Comment
  • Kinder Morgan's Debt Level Should Scare You [View article]
    SR, I have a feeling that some folks on the street may have been quantifying counterparty risks on those contracts sector wide.
    Aug 6, 2015. 01:09 AM | Likes Like |Link to Comment
  • Anthem-Cigna Is All About Accountable Care [View article]
    I'm not sure about the assumption in this article that seems to strictly equate ACO with Medicare Advantage. If that is not the thesis, then some recognition of how the other business segments are competitively related is surely relevant. MA is not even the largest market is it?

    Also, I'm not very sure why anyone thinks three well matched competitors is inferior to one very large and four growth oriented players.
    Aug 5, 2015. 06:28 PM | Likes Like |Link to Comment
  • RSO Preferred Stock - Why Did It Decline Recently? Consider This 10%+ Yielder [View article]
    Thank you very much for the article, and to those commenters sharing their actual DD. I'm long the C preferred, and I'm prepared for the possibility it isn't called. The float spread to LIBOR mitigates being in a really dumb situation down the road.

    It's possible that the Puerto Rico exposure and the future FRB interest rate outlook are combining to affect price action. Does anyone know if they are exposed to energy in their more traditional BDC book?

    I'll add that this one (and similar other elevated risk preferreds) are absolutely perfect for my non-equity barbell strategy.
    Aug 5, 2015. 12:45 PM | 1 Like Like |Link to Comment
  • Why Denbury Resources Is A Good Investment Despite Its Massive Decline [View article]
    I bought a few hundred shares @3.30. I say it bounces hard if oil cooperates. Only playing for a bounce to lower avg cost.
    Aug 5, 2015. 11:24 AM | Likes Like |Link to Comment
  • Gilead's Stock Price, Harvoni Pricing, And The Threat Of Merck- A Physician's Perspective [View article]
    OMG. You handle 'em counselor. I'm trying to preserve my high view of human potential.
    Aug 5, 2015. 11:00 AM | 1 Like Like |Link to Comment
  • Core Laboratories Has A Great Business, But Is It Cheap Enough? [View article]
    Thanks for the article. While it is mentioned, the article is sanguine about debt levels that are worrisome. I don't have a position, but my DD would start with how debt is being managed. Returning capital to shareholders while carrying or increasing debt is NOT a good sign in my experience.
    Aug 5, 2015. 10:57 AM | 2 Likes Like |Link to Comment
  • Baxalta: A Rare Undervalued Biopharmaceutical Company [View article]
    Noted, Chris. I know this suits more investors, but mine is a tax deferred hold so that's my selfishness coming out.
    Aug 5, 2015. 12:05 AM | Likes Like |Link to Comment
  • Why Denbury Resources Is A Good Investment Despite Its Massive Decline [View article]
    I didn't actually think it was directed at me, but the shoe fits. These are trying times for energy. Coal is a real mess, and the supposed beneficiary - natgas - is not much better. Then there's tight oil...

    Other than trading moves in existing long term positions (DNR, OXY, STO) I'm speculating in oil only through Canadian producers where there is at least a currency advantage.

    Oh yeah, I also have some long duration calls in CHK - also underwater.
    Aug 5, 2015. 12:02 AM | Likes Like |Link to Comment
  • Baxalta: A Rare Undervalued Biopharmaceutical Company [View article]
    I'd prefer something other than an all stock deal (I hold this one in a tax deferred account), and I'd also like a better offer - which I think we will see. I'm long both companies, but a lot longer BXLT. I bought BAX last year because I liked the spin-off plan.
    Aug 4, 2015. 09:07 PM | 1 Like Like |Link to Comment
  • Why Denbury Resources Is A Good Investment Despite Its Massive Decline [View article]
    Immediate gratification? Heh. I'd settle for eventual gratification at this point. We still haven't seen the kind of wash out volume that indicates a bottom in the sector, which I find worrisome. OTOH, I've been looking at past oil price corrections, which seem to average 8-16 months to the bottom (throwing out the 1980s market which had other stuff happening). Pluses and minuses to all my forecasts.

    - Unless something different is happening (usually not the case).

    + Unless a mideast blow up interrupts supply security (always possible)
    Aug 4, 2015. 09:01 PM | Likes Like |Link to Comment
  • Gilead's Stock Price, Harvoni Pricing, And The Threat Of Merck- A Physician's Perspective [View article]
    Thanks counselor. Now, if only I could keep my eye on the ball by figuring out some specific indirect beneficiaries of this situation I'd be better off. :)
    Aug 4, 2015. 08:20 PM | Likes Like |Link to Comment
  • Why Denbury Resources Is A Good Investment Despite Its Massive Decline [View article]
    I've been trading it around a core position, so my cost basis has been dropping - but not as fast as the share price. My view of the company has not changed, so I remain long.
    Aug 4, 2015. 08:14 PM | Likes Like |Link to Comment
  • Gilead's Stock Price, Harvoni Pricing, And The Threat Of Merck- A Physician's Perspective [View article]
    I appreciated this article's "in the trenches" view of the effects of cost in assessing treatment options. Without doing so in so many words, it validates the concepts taught in any introductory economics class on the effects of (even inferior) competition in the marketplace. These effects are magnified as the number of players increases.

    I believe we can think a little more broadly about the benefits of competition (I'm a fan of capitalism). I could argue that GILD will be a better company when pressured to grow and excel in the face of increased competition. In any event, whether or not GILD could be seen to benefit from competition, our society does.

    Just one example: think of the downstream benefits to healthcare providers and insurers, or even healthcare REIT investments as treatment costs for their tenants result in increased profits resulting in more secure financial ability to pay for and even increase their facility needs. These kinds of ripple effects result in any number of areas of our economy. Improvement in healthcare treatment (and associated costs) can only result in huge benefits for our economy.

    Right now GILD is in the great position of having the most effective treatment for Hep C. The economics of competition will affect margin, but the data I've seen so far doesn't suggest that they have much to worry about when it comes to competing treatments changing that.
    Aug 4, 2015. 06:36 PM | 1 Like Like |Link to Comment
  • Structurally Light On Growth, Baxter Has A Lot Of Work Ahead [View article]
    http://bit.ly/1K2KCGT

    If I were a healthcare purchasing agent, I wouldn't touch Hospira infusion products...
    Aug 4, 2015. 06:02 PM | Likes Like |Link to Comment
COMMENTS STATS
3,602 Comments
2,885 Likes